Cross-sectional analysis of consumer-facing mHealth apps associated with inhaler monitoring for asthma.

OBJECTIVE: This study aimed to describe the current landscape of consumer-directed mHealth apps that communicate with inhalers for asthma. METHODS: We performed a cross-sectional and systematic analysis of Google Play and the Apple App Stores to identify apps that are consumer-direct and available in English, intended for patients with asthma and communicate with an inhaler-based sensor. We collected information about each app using the app stores and publicly available manufacturer websites. We reported the results descriptively. RESULTS: We identified 6 apps, released as early as 2012. Of these, 5 apps require an external sensor available over the counter to be attached to the patient's inhaler, and 1 app communicates with a prescription-only inhaler that has a built-in sensor and will be dispensed from the pharmacy. Aside from passively monitoring inhaler adherence, all apps facilitate provider communication; serve as a diary; and use notifications, reminders, or alarms for things such as inhaler dose reminders. Additional features vary across apps, including direct pharmacy access for refill requests and telehealth and artificial intelligence to predict future asthma exacerbations. CONCLUSION: We identified 6 consumer-directed mHealth apps that communicate with inhalers for asthma management. Pharmacists must be prepared to evaluate these apps, particularly in comparison with the first prescription-only inhaler built to communicate with an mHealth app to be released this year. To do so, further research on the outcomes and use of these apps is needed so that pharmacists can make evidence-based recommendations.

Epinephrine in Cardiac Arrest: Identifying a Potential Limit for Resuscitation.

Introduction: Epinephrine continues to be a fundamental part of the Advanced Cardiac Life Support algorithm despite a lack of evidence that it improves neurologically intact survival. Our aim was both to identify a potential upper limit of epinephrine use in resuscitations and to demonstrate real-world epinephrine use in different patient subgroups. Methods: This was a single-center, retrospective cohort study, conducted between August 1, 2016-July 1, 2021, of patients with medical cardiac arrest who were administered a known number of epinephrine doses. The primary outcome was neurologically intact discharge defined by a modified Rankin scale ≤3, with secondary outcomes of comparing epinephrine doses by age, rhythm, and emergency medical services vs emergency department administration of epinephrine. Results: The study included 1,330 patients, with 184 patients (13.8%) surviving to neurologically intact discharge. The primary outcome of neurologically intact discharge was found in 89 (65.4%) patients in the zero epinephrine dose group, 75 (20.0%) in the 1-3 dose group, 15 (4.3%) in the 4-6 dose group, and one (0.002%) in the ≥7 dose group (P < 0.001). Patients received similar amounts of epinephrine when stratified by age, while patients with shockable rhythms received more epinephrine than patients with non-shockable rhythms. Conclusion: There was a significant decrease in neurologically intact discharge with increasing number of epinephrine doses, and our data suggests that seven or more doses of epinephrine is almost always futile. While further prospective studies are needed, clinicians should consider epinephrine doses when weighing the futility or benefit of continued resuscitation efforts.

Evaluation of the safety of a novel peripheral vasopressor pilot program and the impact on central line placement in medical and surgical intensive care units.

PURPOSE: The purpose of this quality improvement project was to evaluate the safety and feasibility of peripheral vasopressor administration in an attempt to minimize the placement and improve early removal of unnecessary central lines to reduce central line-associated bloodstream infection (CLABSI) rates. METHODS: A retrospective chart review was conducted on patients who received vasopressors via peripheral infusion over 3 months, starting at the time of guideline implementation. RESULTS: We identified 129 vasopressor orders among 79 patients that were administered peripherally. Among these orders, 3 events were documented as possible extravasation events. Forty-five patients (57%) did not require central line placement due to increasing vasopressor requirements. Standard utilization ratio data suggest minimal central line impact of the protocol implementation. December 2020 to February 2021 was associated with a large second peak of coronavirus disease 2019 (COVID-19) in our region. Utilization of central lines was less than predicted in December 2020 to February 2021 in 2 of our 3 intensive care units (ICUs); however, the differences were statistically significant on only 3 occasions. In the third ICU, utilization was greater than predicted, but this unit housed a majority of the most critically ill patients with COVID-19. CONCLUSION: This study suggests that short-term use of select vasopressors at conservative doses is safe for peripheral administration and points toward efficacy at preventing central line placement. Further analysis is required to confirm efficacy.

Systematic Review of mHealth Applications That Interface with Inhaler Sensors in Asthma.

BACKGROUND: A better understanding of outcomes associated with mobile health (mHealth) applications (apps) for asthma self-management that pair with inhaler sensor technology is needed for clinicians to practice evidence-based medicine. OBJECTIVE: To evaluate the effects of mHealth apps that integrate with an inhaler-based sensor on outcomes of patients with asthma. METHODS: We performed a systematic review in GooglePlay and Apple App stores for consumer-facing mHealth apps for asthma management that pair with an inhaler-based sensor. We then searched for evidence evaluating these apps via PubMed and Cochrane Central (January 2007-May 2020), bibliographies on product websites, and www.clinicaltrials.gov. We included studies in patients with asthma evaluating apps discovered in the app stores on adherence or a health outcome of interest, and qualitatively summarized evidence. RESULTS: We identified 6 mHealth apps and screened 2594 citations for evidence on these apps; 7 studies of 2 apps were included. Interventions modestly improved maintenance inhaler adherence and reduced rescue inhaler use but did not impact Asthma Control Test scores. Effects on exacerbations, quality of life, and pulmonary function were not evaluated in these studies. CONCLUSIONS: The current literature evaluating mHealth apps paired with inhaler-based sensors focuses on a small number of available products and has limitations in quality. Positive effects on rescue inhaler use, inhaler adherence, and patient satisfaction were found. However, more comprehensive evaluation of products and their impact on health outcomes is needed before clinicians and patients can weigh the benefits against resources needed to adopt these technologies.

Suspected donepezil toxicity: A case report.

Donepezil toxicity can present similarly to beta-blocker overdose and colitis. Symptoms include confusion, diaphoresis, and bradycardia. In patients with suspected medication-related toxicities, it is important to consider all possible causative agents in the active medication list.